Pozen Says Yosprala On Track For Approval Despite Losing Sanofi As Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi backed out of a commercialization deal for the fixed-dose aspirin/omeprazole combination just weeks before the drug’s Dec. 30 PDUFA date.